Trial Profile
A Phase II and Pilot Trial of PD-1 Blockade With Pembrolizumab (MK-3475) in Patients With Resectable or Unresectable Desmoplastic Melanoma (DM)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Nov 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms SWOG 1512
- 23 Sep 2023 Planned End Date changed from 28 Jun 2024 to 21 Sep 2024.
- 30 Jun 2023 Planned End Date changed from 1 Dec 2028 to 28 Jun 2024.
- 19 Apr 2023 Results from S1512 Cohort B in patients with metastatic DM presented at the 114th Annual Meeting of the American Association for Cancer Research